Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0REEBA |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | huXBR1-402 |
|||||
| Antigen Name | ROR1 |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
NBE-002 [Phase 1/2 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligibility requires age ≥18, progressive advanced tumors (Phase 1: any solid tumor refractory to standard therapy; Phase 2: TNBC ≤3L or other solid tumors ≤3L), measurable disease (Phase 2 only), ECOG 0-2 (Phase 1) or 0-1 (Phase 2), and adequate organ function. Key exclusions include prior ROR1-targeting therapy, active CNS metastases, unresolved Grade >1 toxicity from prior treatments, recent anticancer therapies/surgeries, significant comorbidities, and secondary malignancies within 3 years.
Click to Show/Hide
|
||||
| Administration Dosage |
NBE-002 will be given intravenously on Day 1 of repeated 28-day cycles.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04441099 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description |
A First-in-Human, Phase 1/2 Study of NBE-002, an Anti-ROR1 Antibody Drug Conjugate, in Patients With Advanced Solid Tumors
|
||||
| Primary Endpoint |
The Phase 1 portion focuses on determining the RP2D through DLT assessments over 48 months, while Phase 2 evaluates anti-tumor activity per RECIST v1.1 for up to 60 months.
|
||||
| Other Endpoint |
Safety monitoring (CTCAE v5.0) and preliminary efficacy (RECIST v1.1) run through 48-60 months, with additional PK (NBE-002 concentrations) and immunogenicity (anti-drug antibodies) profiling.
|
||||